Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
November 27, 2024 7:14 AM ESTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR).
The analyst comments "Arrowhead has announced a new global licensing and collaboration agreement with Sarepta Therapeutics (unrated). We believe that this is a positive development for... More



